Denmark · Delayed Price · Currency is DKK Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of DKK 112.95 billion. The enterprise value is 136.56 billion.
| Market Cap | 112.95B |
| Enterprise Value | 136.56B |
Important Dates
The last earnings date was Tuesday, February 17, 2026.
| Earnings Date | Feb 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 61.57 million shares outstanding. The number of shares has decreased by -3.04% in one year.
| Current Share Class | 61.57M |
| Shares Outstanding | 61.57M |
| Shares Change (YoY) | -3.04% |
| Shares Change (QoQ) | +1.68% |
| Owned by Insiders (%) | 1.15% |
| Owned by Institutions (%) | 58.47% |
| Float | 60.85M |
Valuation Ratios
The trailing PE ratio is 18.76 and the forward PE ratio is 23.82. Genmab's PEG ratio is 3.23.
| PE Ratio | 18.76 |
| Forward PE | 23.82 |
| PS Ratio | 4.77 |
| PB Ratio | 3.04 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.45 |
| P/OCF Ratio | 14.97 |
| PEG Ratio | 3.23 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.43, with an EV/FCF ratio of 18.68.
| EV / Earnings | 22.29 |
| EV / Sales | 5.77 |
| EV / EBITDA | 16.43 |
| EV / EBIT | 17.17 |
| EV / FCF | 18.68 |
Financial Position
The company has a current ratio of 2.02, with a Debt / Equity ratio of 0.93.
| Current Ratio | 2.02 |
| Quick Ratio | 2.01 |
| Debt / Equity | 0.93 |
| Debt / EBITDA | 4.15 |
| Debt / FCF | 4.72 |
| Interest Coverage | 20.49 |
Financial Efficiency
Return on equity (ROE) is 17.53% and return on invested capital (ROIC) is 16.61%.
| Return on Equity (ROE) | 17.53% |
| Return on Assets (ROA) | 8.10% |
| Return on Invested Capital (ROIC) | 16.61% |
| Return on Capital Employed (ROCE) | 10.92% |
| Weighted Average Cost of Capital (WACC) | 6.82% |
| Revenue Per Employee | 7.96M |
| Profits Per Employee | 2.06M |
| Employee Count | 2,973 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 17.63 |
Taxes
In the past 12 months, Genmab has paid 1.53 billion in taxes.
| Income Tax | 1.53B |
| Effective Tax Rate | 20.02% |
Stock Price Statistics
The stock price has increased by +14.49% in the last 52 weeks. The beta is 0.80, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | +14.49% |
| 50-Day Moving Average | 2,017.66 |
| 200-Day Moving Average | 1,757.37 |
| Relative Strength Index (RSI) | 42.24 |
| Average Volume (20 Days) | 126,971 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genmab had revenue of DKK 23.66 billion and earned 6.13 billion in profits. Earnings per share was 97.77.
| Revenue | 23.66B |
| Gross Profit | 22.15B |
| Operating Income | 7.95B |
| Pretax Income | 7.66B |
| Net Income | 6.13B |
| EBITDA | 8.21B |
| EBIT | 7.95B |
| Earnings Per Share (EPS) | 97.77 |
Balance Sheet
The company has 10.91 billion in cash and 34.51 billion in debt, with a net cash position of -23.61 billion or -383.38 per share.
| Cash & Cash Equivalents | 10.91B |
| Total Debt | 34.51B |
| Net Cash | -23.61B |
| Net Cash Per Share | -383.38 |
| Equity (Book Value) | 37.19B |
| Book Value Per Share | 603.58 |
| Working Capital | 9.27B |
Cash Flow
In the last 12 months, operating cash flow was 7.54 billion and capital expenditures -235.35 million, giving a free cash flow of 7.31 billion.
| Operating Cash Flow | 7.54B |
| Capital Expenditures | -235.35M |
| Free Cash Flow | 7.31B |
| FCF Per Share | 118.70 |
Margins
Gross margin is 93.60%, with operating and profit margins of 33.60% and 25.89%.
| Gross Margin | 93.60% |
| Operating Margin | 33.60% |
| Pretax Margin | 32.37% |
| Profit Margin | 25.89% |
| EBITDA Margin | 34.68% |
| EBIT Margin | 33.60% |
| FCF Margin | 30.89% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.04% |
| Shareholder Yield | 3.04% |
| Earnings Yield | 5.42% |
| FCF Yield | 6.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genmab has an Altman Z-Score of 2.48 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.48 |
| Piotroski F-Score | 4 |